Goal 3: Advance Translational Research

Development of Novel Apheresis Adsorption Technologies to More Effectively and Safely Treat Hematologic Diseases

Current FDA approved apheresis technology currently uses elutriation/centrifugation separation techniques to remove pathologic cellular and/or plasma elements. These techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to treat many of diseases using apheresis has not changed since the development of the modern cell separator in the 1980s. Development of novel apheresis technologies are needed to selectively remove pathologic cellular and/or plasma elements to improve current treatment modalities and/or provide novel treatment approaches in these patients.

Tags (Keywords associated with the idea)


93 net votes
112 up votes
19 down votes
Idea No. 657